Dong, Huan
Huang, Zichong
Yang, Dong
Li, Zhiru
Huang, Heqing
Meng, Zhen
Qin, Yutao
Kang, Min
Funding for this research was provided by:
National Natural Science Foundation of China (No. 71964003, 71964003, 81760542, 82160467)
Natural Science Foundation of Guangxi Zhuang Autonomous Region (No.2JJA141048)
Research Foundation of the Science and Technology Department of Guangxi Province, China (No.2GXNSFAA380252, 2018AB61001 and 2019GXNSFAA185040)
Research Foundation of the Health Department of Guangxi Province, China (No.S2018087)
Guangxi Medical University Training Program for Distinguished Young Scholars (2017)
Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University (2016)
Article History
Received: 23 March 2023
Accepted: 27 June 2023
First Online: 18 July 2023
Declarations
:
: The authors declare no competing interests.
: EBV, Epstein-Barr virus; PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; CRP, C-reactive protein; LDH, lactate dehydrogenase; NPC, nasopharyngeal carcinoma; OS, overall survival; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival; HRG, high risk group; MRG, medium risk group; LRG,low risk group; ROC, receiver operating characteristic; AUC, area under the curve; IMRT, intensity-modulated radiotherapy; CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; AC, adjuvant chemotherapy; HR, hazard ratio; CI, confidence interval.
: <b>Ethics approval and consent to participate</b>.
: This study was conducted in accordance with the Helsinki Declaration and approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. And this was a retrospective study, so the informed consent was waived by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. Participant information is confidential.
: <b>Consent for publication</b>.
: Not applicable.